Search tips
Search criteria

Results 1-7 (7)

Clipboard (0)

Select a Filter Below

Year of Publication
Document Types
1.  Increasing Frequency of Feline Cytauxzoonosis Cases Diagnosed in Western Kentucky From 2001–2011 
Veterinary parasitology  2013;198(0):10.1016/j.vetpar.2013.08.012.
Feline cytauxzoonosis is a rapidly progressing and usually fatal disease in domestic cats caused by the tick-borne pathogen, Cytauxzoon felis. The primary reservoir host for this protozoan parasite is the bobcat (Lynx rufus). In this retrospective study, we have examined the positive cases of feline cytauxzoonosis identified at Murray State University’s Breathitt Veterinary Center, a regional diagnostic facility located in Hopkinsville, Kentucky, between January 2001 and December 2011. Center records reveal that there has been an increase in the rate of diagnosis of domestic feline infection with C. felis over that 10-year span with the majority of cases (75%) occurring between 2006–2011. The infection was diagnosed from March through October and showed a single peak in May, corresponding well with the questing period for the lone star tick, Amblyomma americanum, a known vector of C. felis.
PMCID: PMC3836630  PMID: 24035030
Cytauxzoon felis; Cytauxzoonosis
2.  Interventional Effects of Plumbagin on Experimental Ulcerative Colitis in Mice 
Journal of natural products  2013;76(6):1001-1006.
Plumbagin (1) is a naphthoquinone constituent of plants that have been used in traditional systems of medicine since ancient times. In the present study, the role of 1 was examined on the amelioration of ulcerative colitis, an inflammatory bowel disease that is not curable currently. Plumbagin was tested at a dose of 6-10 mg/kg body weight in acute and chronic disease models. Diseased mice receiving 1 at 8-10 mg/kg demonstrated a significant suppression of disease symptoms in both models. However, body weight loss was not restored in either of the models. Levels of proinflammatory cytokines (TNF-α, IFN-γ, and IL-17) were reduced significantly by 1 in mice suffering from chronic disease, while cytokine levels remained unaffected in mice with acute disease. However, the percentage of inflammatory (CD14+/CD16+) monocytes present in peripheral blood was significantly reduced (>three-fold) (p <0.05) in treatment groups relative to controls in the acute model. Histological evaluations exhibited the restoration of goblet cells, crypts, and the submucosa along with a significant reduction in monocyte aggregation in colon sections from mice receiving treatment with 1. Restoration in colon size was also observed in the treatment groups.
PMCID: PMC3752897  PMID: 23742275
5.  Growth Hormone Treatment of Growth Failure in Pediatric Patients with Crohn’s Disease 
The Journal of pediatrics  2008;153(5):651-658.e3.
We determined the impact of human growth hormone (GH) injections on growth velocity in growth impaired children with Crohn’s Disease (CD).
Study design
Ten children and adolescents (12.6±4.5 years; 6 male) with CD and poor height growth were treated with open label recombinant GH 0.043 mg/kg/day SQ for one year. Patients were retrospectively matched with untreated patients (3 comparisons per case) by race, age, sex, and baseline height. Primary endpoint was height velocity; secondary endpoints were disease activity, body composition, and bone density by DEXA scan.
Mean height velocity in GH-treated patients increased by 5.33±3.40 (mean ± SD) cm/yr during the year of GH compared with 0.96±3.52 cm/yr in the comparison group (p=0.03). Height Z score increased in the treated group by 0.76±0.38 compared with 0.16±0.40 in the comparison group (p<0.01), and weight Z score increased 0.81±0.89 compared with 0.00±0.57 (p<0.01). Bone density revealed an increase of the lumbar spine Z score by 0.31±0.33 (p=0.03 vs baseline).
GH treatment increases height velocity and potentially enhances bone mineralization in children with CD. A randomized controlled trial in a large cohort of children is required to determine the ultimate impact of GH treatment.
PMCID: PMC2590584  PMID: 18589450
DEXA; bone density; height; inflammatory bowel disease; osteoporosis
6.  Sensitivity and Specificity of the ViroSeq Human Immunodeficiency Virus Type 1 (HIV-1) Genotyping System for Detection of HIV-1 Drug Resistance Mutations by Use of an ABI PRISM 3100 Genetic Analyzer 
Journal of Clinical Microbiology  2005;43(2):813-817.
The ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system is an integrated system for identification of drug resistance mutations in HIV-1 protease and reverse transcriptase (RT). Reagents are included for sample preparation, reverse transcription, PCR amplification, and sequencing. Software is provided to assemble and edit sequence data and to generate a drug resistance report. We determined the sensitivity and specificity of the ViroSeq system for mutation detection using an ABI PRISM 3100 genetic analyzer with a set of clinical samples and recombinant viruses. Twenty clinical plasma samples (viral loads, 1,800 to 10,500 copies/ml) were characterized by cloning and sequencing individual viral variants. Twelve recombinant-virus samples (viral loads, approximately 2,000 to 5,000 copies/ml) were also prepared. Eleven recombinant-virus samples contained drug resistance mutations as 40% mixtures. One recombinant-virus sample contained an insertion at codon 69 in RT (100% mutant). Plasma and recombinant-virus samples were analyzed using the ViroSeq system. Each sample was analyzed on three consecutive days at each of three testing laboratories. The sensitivity of mutation detection was 99.65% for the clinical plasma samples and 99.7% for the recombinant-virus preparations. The specificity of mutation detection was 99.95% for the clinical samples and 100% for the recombinant-virus mixtures. The base calling accuracy of the 3100 instrument was 99.91%. Mutations in clinical plasma samples and recombinant-virus samples were detected with high sensitivity and specificity, including mutations present as mixtures. This report supports the use of the ViroSeq system for identification of drug resistance mutations in HIV-1 protease and RT genes.
PMCID: PMC548107  PMID: 15695685
7.  Comparison of Oral Fluid Collectors for Use in a Rapid Point-of-Care Diagnostic Device 
Orally based diagnostic testing is emerging as an alternative, noninvasive method for analyzing a variety of analytes. These analytes include pathogens, antibodies, drugs, and nucleic acids. In the present study we developed a protocol for evaluation of collectors that could be used in orally based, point-of-care diagnostics. A performance comparison was carried out with a number of commercially available collectors, and their ability to deliver fluid, proteins, bacteria, and nucleic acid from pathogens compatible with PCR was assessed. The collectors were all capable of picking up and delivering test materials, albeit at various levels.
PMCID: PMC515263  PMID: 15358651

Results 1-7 (7)